Abstract: Objective To compare the efficacy of domestic and imported entecavir on patients with hepatitis B-induced acute-on-chronic liver failure. Methods 105 patients with hepatitis B-induced acute-on-chronic liver failure between July 2011 and April 2016 in our hospital were included in this clinical trial,and 54 of them were treated with domestic entecavir as observation group,and another 51 patients were treated with imported entecavir as control group. Serum HBV DNA,liver function index,the mortality rate after 12 week treatment were compared between the two groups. Results At the end of 12 weeks,serum HBV DNA levels in the two groups were significantly decreased and the negative rate in the observation group was 72.22% （39/54）,no significant difference as compared to 72.55%（37/51） in the control grou（x²=0.03,P=0.86）;total serum bilirubin,alanine aminotransferase,aspartate aminotransferase levels decreased to（66.59±10.78）μmol/L,（68.32±11.57）U/L,（46.77±18.82）U/L,the serum albumin levels increased to（37.18±4.29）g/L,and PT decreased to（15.34±1.28） s,all of which were not significantly different to those in the control group [（65.32±9.18）μmol/L,（67.07±9.62）U/L,（44.17±14.18）U/L,（37.51±4.30）g/L,（15.68±1.27）,P>0.05];the mortality in the two groups were 31.48%（17/54） and 31.37%（16/51）,and there was no significant difference between the two groups（x²=0.04,P=0.84）. No serious adverse event occurred in the two groups. Conclusions The domestic is equally effective as the imported entecavir in the treatment of patients with hepatitis B-induced acute-on-chronic liver failure.

Key words: Acute-on-chronic liver failure, Hepatitis B, Entecavir, Efficacy